The drug-maker Lupin is looking to make one more acquisition in this market. Lupin already has a wholly-owned subsidiary, Kyowa Pharmaceuticals in Japan.
Lupin will make an acquisition in the area of interest only and with a strategic reason to it. The company has not decided the size of the acquisition yet. For the three months under review, Kyowa Pharmaceuticals grew by 22 per cent, clocking net sales of Rs 156 crore, and contributed 11 per cent to Lupin's consolidated revenues.
Lupin would look to launch another 8-10 products in the forthcoming year. The company's strategy of differentiated products in segments such as oral contraceptives and ophthalmology are set to deliver. The first basket of products would come into the market in September. The company's research-spend stands pegged at about 8 per cent of sales.crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1800.65 |
| Dr. Reddys Lab | 1277.05 |
| Cipla | 1372.75 |
| Zydus Lifesciences | 1078.40 |
| Lupin | 2277.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: